Equities research analysts expect Outlook Therapeutics, Inc. (NASDAQ:OTLK) to post sales of $630,000.00 for the current quarter, according to Zacks. Two analysts have issued estimates for Outlook Therapeutics’ earnings, with estimates ranging from $600,000.00 to $650,000.00. The business is expected to announce its next earnings results on Tuesday, December 17th.
On average, analysts expect that Outlook Therapeutics will report full year sales of $2.92 million for the current year, with estimates ranging from $2.90 million to $2.94 million. For the next year, analysts forecast that the business will post sales of $3.30 million, with estimates ranging from $2.60 million to $4.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Outlook Therapeutics.
A number of equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of Outlook Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. LADENBURG THALM/SH SH started coverage on Outlook Therapeutics in a report on Wednesday, September 11th. They issued a “buy” rating and a $9.00 price target on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $7.79.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Cormorant Asset Management LP purchased a new position in Outlook Therapeutics in the second quarter worth $32,000. Virtu Financial LLC acquired a new stake in shares of Outlook Therapeutics in the 3rd quarter worth $83,000. LVW Advisors LLC boosted its position in shares of Outlook Therapeutics by 37.6% in the 3rd quarter. LVW Advisors LLC now owns 389,088 shares of the company’s stock worth $580,000 after purchasing an additional 106,293 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Outlook Therapeutics by 712.1% during the 2nd quarter. Vanguard Group Inc. now owns 396,001 shares of the company’s stock worth $824,000 after buying an additional 347,238 shares during the last quarter. Institutional investors own 3.16% of the company’s stock.
Shares of NASDAQ OTLK traded down $0.27 during midday trading on Friday, reaching $1.32. 36,643 shares of the company’s stock traded hands, compared to its average volume of 184,195. The company has a market cap of $29.36 million, a price-to-earnings ratio of -0.12 and a beta of -0.74. The stock’s 50 day simple moving average is $1.20 and its 200-day simple moving average is $1.78. Outlook Therapeutics has a one year low of $0.85 and a one year high of $10.96.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Read More: What Are Treasury Bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.